Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
Stockchase Opinions

The Panic-Proof Portfolio (Stockchase Research)Simulations Plus, Inc.SLPTOP PICKApr 13, 2021

Stockchase Research Editor: Michael O'Reilly SLP is a $1.2 billion healthcare software company that provides modeling and simulation products to drug companies and biotechs and other sectors. Recently reported revenues were up 27% on the year and net income rose 49%. Their recurring revenue model helps produce 78% gross margins and it carries minimal long term debt. It pays a small dividend, backed by a 45% payout ratio. We would buy this with a stop loss at $40, looking to achieve $83 -- upside potential over 40%. Yield 0.38% (Analysts’ price target is $82.50)
$58.80

Stock price when the opinion was issued

$18.30

As of Jun 18, 2026. Market Open.

biotechnology
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Apr 13/21, Down 32%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with SLP has triggered its stop at $40. We recommend covering the remaining position at this time. We will look for better opportunities.